Bulk Manufacturer of Controlled Substances Application: Chattem Chemicals, 11557-11558 [2021-03836]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 36 / Thursday, February 25, 2021 / Notices
investigation. The Commission is
soliciting submissions on public interest
issues raised by the recommended relief
should the Commission find a violation.
This notice is soliciting comments from
the public only.
FOR FURTHER INFORMATION CONTACT:
Benjamin S. Richards, Esq., Office of the
General Counsel, U.S. International
Trade Commission, 500 E Street SW,
Washington, DC 20436, telephone (202)
708–5453. Copies of non-confidential
documents filed in connection with this
investigation may be viewed on the
Commission’s electronic docket (EDIS)
at https://edis.usitc.gov. For help
accessing EDIS, please email
EDIS3Help@usitc.gov. General
information concerning the Commission
may also be obtained by accessing its
internet server at https://www.usitc.gov.
Hearing-impaired persons are advised
that information on this matter can be
obtained by contacting the
Commission’s TDD terminal on (202)
205–1810.
SUPPLEMENTARY INFORMATION: Parties are
to file public interest submissions
pursuant to 19 CFR 210.50(a)(4). Section
337 of the Tariff Act of 1930 provides
that, if the Commission finds a
violation, it shall exclude the articles
concerned from the United States:
unless, after considering the effect of such
exclusion upon the public health and
welfare, competitive conditions in the United
States economy, the production of like or
directly competitive articles in the United
States, and United States consumers, it finds
that such articles should not be excluded
from entry.
19 U.S.C. 1337(d)(1). A similar
provision applies to cease and desist
orders. 19 U.S.C. 1337(f)(1).
The Commission is soliciting
submissions on public interest issues
raised by the recommended relief
should the Commission find a violation,
specifically: A limited exclusion order
directed to certain collapsible and
portable furniture imported, sold for
importation, and/or sold after
importation by respondents Denovo
Brands, LLC; Zhenli (Zhangzhou)
Industrial Co., Ltd. (‘‘Denovo’’); Meike
(Qingdao) Leisure Products Co., Ltd.;
Westfield Outdoor, Inc. d/b/a Westfield
Outdoors (‘‘Westfield’’); and MacSports
Inc. (‘‘MacSports’’); and cease and desist
orders directed to Denovo, Westfield,
and MacSports.
The Commission is interested in
further development of the record on
the public interest in this investigation.
Accordingly, members of the public are
invited to file submissions of no more
than five (5) pages, inclusive of
attachments, concerning the public
VerDate Sep<11>2014
17:04 Feb 24, 2021
Jkt 253001
interest in light of the ALJ’s
Recommended Determination on
Remedy and Bonding issued in this
investigation on February 18, 2021.
Comments should address whether
issuance of the recommended remedial
orders in this investigation, should the
Commission find a violation, would
affect the public health and welfare in
the United States, competitive
conditions in the United States
economy, the production of like or
directly competitive articles in the
United States, or United States
consumers.
In particular, the Commission is
interested in comments that:
(i) explain how the articles potentially
subject to the recommended remedial
orders are used in the United States;
(ii) identify any public health, safety,
or welfare concerns in the United States
relating to the recommended orders;
(iii) identify like or directly
competitive articles that complainant,
its licensees, or third parties make in the
United States which could replace the
subject articles if they were to be
excluded;
(iv) indicate whether complainant,
complainant’s licensees, and/or thirdparty suppliers have the capacity to
replace the volume of articles
potentially subject to the recommended
orders within a commercially
reasonable time; and
(v) explain how the recommended
orders would impact consumers in the
United States.
Written submissions must be filed no
later than by close of business on March
22, 2021.
Persons filing written submissions
must file the original document
electronically on or before the deadlines
stated above. The Commission’s paper
filing requirements in 19 CFR 210.4(f)
are currently waived. 85 FR 15798
(March 19, 2020). Submissions should
refer to the investigation number (‘‘Inv.
No. 337–TA–1178’’) in a prominent
place on the cover page and/or the first
page. (See Handbook for Electronic
Filing Procedures, https://
www.usitc.gov/documents/handbook_
on_filing_procedures.pdf.) Persons with
questions regarding filing should
contact the Secretary (202–205–2000).
Any person desiring to submit a
document to the Commission in
confidence must request confidential
treatment. All such requests should be
directed to the Secretary to the
Commission and must include a full
statement of the reasons why the
Commission should grant such
treatment. See 19 CFR 201.6. Documents
for which confidential treatment by the
Commission is properly sought will be
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
11557
treated accordingly. All information,
including confidential business
information and documents for which
confidential treatment is properly
sought, submitted to the Commission for
purposes of this Investigation may be
disclosed to and used: (i) By the
Commission, its employees and Offices,
and contract personnel (a) for
developing or maintaining the records
of this or a related proceeding, or (b) in
internal investigations, audits, reviews,
and evaluations relating to the
programs, personnel, and operations of
the Commission including under 5
U.S.C. Appendix 3; or (ii) by U.S.
government employees and contract
personnel, solely for cybersecurity
purposes. All contract personnel will
sign appropriate nondisclosure
agreements. All nonconfidential written
submissions will be available for public
inspection on EDIS.
This action is taken under the
authority of section 337 of the Tariff Act
of 1930, as amended (19 U.S.C. 1337),
and in Part 210 of the Commission’s
Rules of Practice and Procedure (19 CFR
part 210).
By order of the Commission.
Issued: February 19, 2021.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2021–03855 Filed 2–24–21; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–789]
Bulk Manufacturer of Controlled
Substances Application: Chattem
Chemicals
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Chattem Chemicals has
applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before April 26, 2021. Such persons
may also file a written request for a
hearing on the application on or before
April 26, 2021.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
SUMMARY:
E:\FR\FM\25FEN1.SGM
25FEN1
11558
Federal Register / Vol. 86, No. 36 / Thursday, February 25, 2021 / Notices
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
In
accordance with 21 CFR 1301.33(a), this
is notice that on July 20, 2020, Chattem
Chemicals 3801 Saint Elmo Avenue,
Chattanooga, Tennessee 37409, applied
to be registered as a bulk manufacturer
of the following basic class(es) of
controlled substance(s):
SUPPLEMENTARY INFORMATION:
Controlled substance
Drug
code
Gamma Hydroxybutyric Acid ....
Marihuana .................................
Tetrahydrocannabinols .............
4-Methoxyamphetamine ...........
Dihydromorphine .......................
Norlevorphanol ..........................
Amphetamine ............................
Methamphetamine ....................
Lisdexamfetamine .....................
Methylphenidate ........................
ANPP (4-Anilino-N-phenethyl-4piperidine).
Phenylacetone ..........................
Cocaine .....................................
Codeine .....................................
Dihydrocodeine .........................
Oxycodone ................................
Hydromorphone ........................
Hydrocodone .............................
Levorphanol ..............................
Meperidine ................................
Meperidine intermediate–A .......
Meperidine intermediate–B .......
Meperidine intermediate–C .......
Methadone ................................
Methadone intermediate ...........
Morphine ...................................
Oripavine ...................................
Thebaine ...................................
Opium, powdered .....................
Opium, granulated ....................
Oxymorphone ...........................
Noroxymorphone ......................
Racemethorphan ......................
Alfentanil ...................................
Remifentanil ..............................
Sufentanil ..................................
Tapentadol ................................
Fentanyl ....................................
Schedule
2010
7360
7370
7411
9145
9634
1100
1105
1205
1724
8333
I
I
I
I
I
I
II
II
II
II
II
8501
9041
9050
9120
9143
9150
9193
9220
9230
9232
9233
9234
9250
9254
9300
9330
9333
9639
9640
9652
9668
9732
9737
9739
9740
9780
9801
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
[FR Doc. 2021–03836 Filed 2–24–21; 8:45 am]
BILLING CODE 4410–09–P
VerDate Sep<11>2014
17:04 Feb 24, 2021
Jkt 253001
Drug Enforcement Administration
[Docket No. DEA–791]
Bulk Manufacturer of Controlled
Substances Application: S&B Pharma,
Inc.
Drug Enforcement
Administration, Justice.
AGENCY:
ACTION:
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before April 26, 2021. Such persons
may also file a written request for a
hearing on the application on or before
April 26, 2021.
DATES:
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
ADDRESSES:
In
accordance with 21 CFR 1301.33(a), this
is notice that on November 11, 2020,
S&B Pharma, Inc., 405 South Motor
Avenue, Azusa, California 91702–3232,
applied to be registered as an bulk
manufacturer of the following basic
class(es) of controlled substance(s):
SUPPLEMENTARY INFORMATION:
Gamma Hydroxybutyric Acid ....
Tetrahydrocannabinols .............
Amphetamine ............................
Methamphetamine ....................
Lisdexamfetamine .....................
Methylphenidate ........................
Pentobarbital .............................
4-Anilino-N-phenethyl-4-piperidine (ANPP).
Tapentadol ................................
Fentanyl ....................................
Drug
code
Schedule
7360
7370
1100
1105
1205
1724
2270
8333
I
I
II
II
II
II
II
II
9780
9801
II
II
The company plans to manufacture
the listed controlled substances in bulk
for use in product development and for
commercial sales to its customers. In
reference to drug code 7360 (Marihuana)
and 7370 (Tetrahydrocannabinols), the
company plans to bulk manufacture
both as synthetic substances. No other
Frm 00064
Fmt 4703
DEPARTMENT OF JUSTICE
[Docket No. DEA798]
Notice of application.
Controlled substance
BILLING CODE 4410–09–P
Drug Enforcement Administration
S&B Pharma, Inc., has applied
to be registered as a bulk manufacturer
of basic class(es) of controlled
substance(s). Refer to Supplemental
Information listed below for further
drug information.
PO 00000
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021–03837 Filed 2–24–21; 8:45 am]
SUMMARY:
The company plans to manufacturer
the listed controlled substances in bulk
for distribution and sale to its
customers.
In reference to drug code 7360
(Marihuana) and 7370
(Tetrahydrocannabinols), the company
plans to bulk manufacture these drugs
as a synthetic. No other activities for
this drug code are authorized for this
registration.
William T. McDermott,
Assistant Administrator.
activity for these drug codes is
authorized for this registration.
DEPARTMENT OF JUSTICE
Sfmt 4703
Importer of Controlled Substances
Application: Myonex Inc
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Myonex Inc has applied to be
registered as an importer of basic
class(es) of controlled substance(s).
Refer to Supplemental Information
listed below for further drug
information.
SUMMARY:
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before March 29, 2021. Such persons
may also file a written request for a
hearing on the application on or before
March 29, 2021.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for a hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on January 6, 2021,
Myonex Inc, 48 East Main Street,
Norristown, Pennsylvania 19401–4915,
applied to be registered as an importer
of the following basic class(es) of
controlled substance(s):
DATES:
Controlled substance
Amphetamine .................
Lisdexamfetamine ..........
Methylphenidate .............
E:\FR\FM\25FEN1.SGM
25FEN1
Drug
code
Schedule
1100
1205
1724
II
II
II
]]>Agencies
[Federal Register Volume 86, Number 36 (Thursday, February 25, 2021)]
[Notices]
[Pages 11557-11558]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-03836]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-789]
Bulk Manufacturer of Controlled Substances Application: Chattem
Chemicals
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Chattem Chemicals has applied to be registered as a bulk
manufacturer of basic class(es) of controlled substance(s). Refer to
Supplementary Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before April 26, 2021.
Such persons may also file a written request for a hearing on the
application on or before April 26, 2021.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal
[[Page 11558]]
Register Representative/DPW, 8701 Morrissette Drive, Springfield,
Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on July 20, 2020, Chattem Chemicals 3801 Saint Elmo
Avenue, Chattanooga, Tennessee 37409, applied to be registered as a
bulk manufacturer of the following basic class(es) of controlled
substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid............... 2010 I
Marihuana............................... 7360 I
Tetrahydrocannabinols................... 7370 I
4-Methoxyamphetamine.................... 7411 I
Dihydromorphine......................... 9145 I
Norlevorphanol.......................... 9634 I
Amphetamine............................. 1100 II
Methamphetamine......................... 1105 II
Lisdexamfetamine........................ 1205 II
Methylphenidate......................... 1724 II
ANPP (4-Anilino-N-phenethyl-4- 8333 II
piperidine).
Phenylacetone........................... 8501 II
Cocaine................................. 9041 II
Codeine................................. 9050 II
Dihydrocodeine.......................... 9120 II
Oxycodone............................... 9143 II
Hydromorphone........................... 9150 II
Hydrocodone............................. 9193 II
Levorphanol............................. 9220 II
Meperidine.............................. 9230 II
Meperidine intermediate-A............... 9232 II
Meperidine intermediate-B............... 9233 II
Meperidine intermediate-C............... 9234 II
Methadone............................... 9250 II
Methadone intermediate.................. 9254 II
Morphine................................ 9300 II
Oripavine............................... 9330 II
Thebaine................................ 9333 II
Opium, powdered......................... 9639 II
Opium, granulated....................... 9640 II
Oxymorphone............................. 9652 II
Noroxymorphone.......................... 9668 II
Racemethorphan.......................... 9732 II
Alfentanil.............................. 9737 II
Remifentanil............................ 9739 II
Sufentanil.............................. 9740 II
Tapentadol.............................. 9780 II
Fentanyl................................ 9801 II
------------------------------------------------------------------------
The company plans to manufacturer the listed controlled substances
in bulk for distribution and sale to its customers.
In reference to drug code 7360 (Marihuana) and 7370
(Tetrahydrocannabinols), the company plans to bulk manufacture these
drugs as a synthetic. No other activities for this drug code are
authorized for this registration.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021-03836 Filed 2-24-21; 8:45 am]
BILLING CODE 4410-09-P
